Stock DNA
Pharmaceuticals & Biotechnology
CNY 12,484 Million (Large Cap)
NA (Loss Making)
NA
0.00%
0.03
-3.03%
2.36
Total Returns (Price + Dividend) 
Porton Pharma Solutions Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
Porton Pharma Solutions Ltd. Faces Challenges Amidst Mixed Financial Results
Porton Pharma Solutions Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has reported a challenging financial performance for the quarter ending March 2025. Despite a notable increase in net sales, the company has faced significant losses, raising concerns among investors.
For the nine-month period, Porton Pharma Solutions Ltd. recorded net sales of CNY 2,442.54 MM, reflecting a growth of 23.04% compared to the previous year. This increase in sales indicates a positive trend in revenue generation, which is crucial for the company's overall performance.
However, the financial results also revealed troubling figures in terms of profitability. The pre-tax profit for the quarter was reported at CNY -0.17 MM, marking a significant loss. Additionally, the net profit for the same period stood at CNY -4.28 MM, indicating that the company is...
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 22.29% vs -29.70% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 121.82% vs -217.03% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -17.50% vs -48.04% in Dec 2023
YoY Growth in year ended Dec 2024 is -308.55% vs -90.94% in Dec 2023






